Findit, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 22, 2023 at 08:33 pm
Share
Findit, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 0.005552 million compared to USD 0.007704 million a year ago. Net loss was USD 0.548033 million compared to USD 0.037319 million a year ago.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.